Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 37kWORD 17k
12 May 2022
E-000805/2022(ASW)
Answer given by Ms Kyriakides
on behalf of the European Commission
Question reference: E-000805/2022

The President of the Commission informed about EU vaccine sharing in 2021 and the targets for 2022 in her address of 6 January 2022(1).

The EU promised to share 250 million doses with low and middle-income countries by the end of 2021 and exceeded this target by sharing in fact 380 million doses, mostly through COVAX. The next target is to share a total of 700 million doses by mid-2022.

By 28 March 2022, EU Member States shared a total of 405.2 million COVID-19 vaccine doses, of which 344.1 million to Gavi for distribution via the COVAX mechanism. Of those doses, 291.5 had already been delivered on the ground in recipient countries, and the remainder is in the pipeline for delivery.

Main beneficiary regions for the EU’s donations via COVAX are the African continent (140.4 million) and Asia and the Pacifics (114.7 million). European neighbourhood regions received 35.5 million via COVAX. The decisions about the allocation of vaccine doses shared to Gavi to recipient countries is the sole responsibility of Gavi.

The Director-General of the World Trade Organisation (WTO) facilitated a discussion on the role of intellectual property in enhancing global access to COVID-19 vaccines with the EU, South Africa, India and the United States.

This process resulted in a compromise outcome that needs to be confirmed for further proceeding by governments of the ‘quad’ (the EU has already given its green light) and then agreed by the broader WTO Membership.

The outcome would allow Members to rapidly authorise a company to manufacture and export COVID-19 vaccines, which would facilitate the production and supply of vaccines in Africa.

(1)https://ec.europa.eu/commission/presscorner/detail/en/STATEMENT_22_121
Last updated: 17 May 2022Legal notice - Privacy policy